# Extracted Content from https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/

Coronavirus Disease 2019 (COVID-19) 2021 Case Definition | CDC  
Skip directly to site content  
Skip directly to search  
An official website of the United States government  
Here's how you know  
Official websites use .gov  
A .gov website belongs to an official government organization in the United States.  
Secure .gov websites use HTTPS  
A  
lock  
(  
) or  
https://  
means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.  
National Notifiable Diseases Surveillance System (NNDSS)  
Explore Topics  
Search  
Search  
Clear Input  
For Everyone  
About About National Notifiable Diseases Surveillance System  
What is Case Surveillance?  
Case Surveillance Modernization  
Infectious Disease Tables  
Non-Infectious Disease Data  
Technical Resource Center  
Case Surveillance in Action  
Contact Us  
View all  
Related Topics:  
NDC Application  
View All  
search  
close search  
search  
National Notifiable Diseases Surveillance System (NNDSS)  
Menu  
Close  
search  
For Everyone  
About About National Notifiable Diseases Surveillance System  
What is Case Surveillance?  
Case Surveillance Modernization  
Infectious Disease Tables  
Non-Infectious Disease Data  
Technical Resource Center  
Case Surveillance in Action  
Contact Us  
View All  
Related Topics  
NDC Application  
View All  
National Notifiable Diseases Surveillance System (NNDSS)  
About About National Notifiable Diseases Surveillance System  
What is Case Surveillance?  
Case Surveillance Modernization  
Infectious Disease Tables  
Non-Infectious Disease Data  
Technical Resource Center  
Case Surveillance in Action  
Contact Us  
View All  
August 24, 2021  
Case Definitions  
Message Mapping Guides  
Supporting Documents for Implementation  
Event Codes & Other Surveillance Resources  
Coronavirus Disease 2019 (COVID-19)  
2021 Case Definition  
Coronavirus Disease 2019 (COVID-19)  
2021 Case Definition  
NOTE:  
A surveillance case definition is a set of uniform criteria used to define a disease for public health surveillance. Surveillance case definitions enable public health officials to classify and count cases consistently across reporting jurisdictions. Surveillance case definitions are not intended to be used by healthcare providers for making a clinical diagnosis or determining how to meet an individual patient’s health needs.  
CSTE Position Statement(s)  
21-ID-01  
Background  
In late December 2019, investigation of a cluster of pneumonia cases of unknown origin in Wuhan, China, resulted in identification of a novel coronavirus. The virus is distinct from, although closely related to, both severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Epidemiologic findings indicate COVID-19 may be less severe  
1  
than SARS or MERS, but evidence suggests that the virus is more contagious than its predecessors. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly identified pathogen, and it is assumed there is no pre-existing human immunity to the virus. There are risk factors that increase an individual’s illness severity.  
Those at highest risk for severe disease and death include people aged over 60 years (especially those 85 years and older) and those with underlying conditions, including but not limited to obesity, hypertension, diabetes, cardiovascular disease, chronic respiratory or kidney disease, immunosuppression from solid organ transplant, and sickle cell disease. A complete list can be found at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html. Disease in children mostly appears to be relatively mild, and there is evidence that a significant proportion of infections across all age groups are asymptomatic, or presymptomatic at the time of testing.  
Cases of COVID-19 in China and the initial U.S. cases in early March 2020 were clustered. Most cases in China occurred in households, and in Washington, for example, a significant cluster was associated with a long-term care facility. By mid-March, multiple areas in the United States reported cases with no direct epidemiologic link to confirmed cases.  
As of March 2021, widespread community transmission of SARS-CoV-2 was documented throughout the United States and globally, and virus variants are circulating widely.  
Because of the rapid advancement in the science of COVID-19 disease and SARS-CoV-2 infection, the Council of State and Territorial Epidemiologists (CSTE) is revising position statement 21-ID-01 to update clinical criteria determined to be indicative of infection; refine laboratory criteria to include genomic sequencing; and acknowledge testing performed in non-traditional settings such as work sites, temporary testing sites, at-home tests, and others. Updated criteria for enumerating a case of reinfection are included based on recent studies indicating that different sequenced SARS-CoV-2 strains can be detected at different time points from weeks to months after initial diagnosis.  
2  
Clinical Criteria  
In the absence of a more likely diagnosis:  
Acute onset or worsening of at least  
two  
of the following symptoms or signs:  
fever (measured or subjective),  
chills,  
rigors,  
myalgia,  
headache,  
sore throat,  
nausea or vomiting,  
diarrhea,  
fatigue,  
congestion or runny nose.  
OR  
Acute onset or worsening of any  
one  
of the following symptoms or signs:  
cough,  
shortness of breath,  
difficulty breathing,  
olfactory disorder,  
taste disorder,  
confusion or change in mental status,  
persistent pain or pressure in the chest,  
pale, gray, or blue-colored skin, lips, or nail beds, depending on skin tone,  
inability to wake or stay awake.  
OR  
Severe respiratory illness with at least  
one  
of the following:  
Clinical or radiographic evidence of pneumonia,  
Acute respiratory distress syndrome (ARDS).  
Laboratory Criteria  
Laboratory evidence using a method approved or authorized by the U.S. Food and Drug Administration (FDA)  
3  
or designated authority\*:  
Confirmatory\*\* laboratory evidence  
:  
Detection of SARS-CoV-2 ribonucleic acid (RNA) in a post-mortem respiratory swab or clinical specimen using a diagnostic molecular amplification test performed by a Clinical Laboratory Improvement Amendments (CLIA)-certified provider,  
OR  
Detection of SARS-CoV-2 by genomic sequencing\*\*\*.  
Presumptive\*\* laboratory evidence:  
Detection of SARS-CoV-2 specific antigen in a post-mortem obtained respiratory swab or clinical specimen using a diagnostic test performed by a CLIA-certified provider.  
Supportive\*\* laboratory evidence:  
Detection of antibody in serum, plasma, or whole blood specific to natural infection with SARS-CoV-2 (antibody to nucleocapsid protein),  
OR  
Detection of SARS-CoV-2 specific antigen by immunocytochemistry in an autopsy specimen,  
OR  
Detection of SARS-CoV-2 RNA or specific antigen using a test performed without CLIA oversight.  
\*On March 13, 2020, the President issued a Memorandum on Expanding State-  
Approved Diagnostic Tests: “Should additional States request flexibility to  
authorize laboratories within the State to develop and perform tests used to  
detect COVID-19, the Secretary shall take appropriate action, consistent with  
law, to facilitate the request.”  
\*\*The terms  
confirmatory  
,  
presumptive  
, and  
supportive  
are categorical labels used here to standardize case classifications for public health surveillance. The terms should not be used to interpret the utility or validity of any laboratory test methodology.  
\*\*\*Some genomic sequencing tests that have been authorized for emergency use  
by the FDA do not require an initial polymerase chain reaction (PCR) result to  
be generated. Genomic sequencing results may be all the public health agency  
receives.  
Epidemiologic Linkage  
One  
or more of the following exposures in the prior 14 days:  
Close contact  
†  
with a confirmed or probable case of COVID-19 disease;  
OR  
Member of an exposed risk cohort as defined by public health authorities during an outbreak or during high community transmission.  
†  
Close contact is generally defined as being within 6 feet for at least 15 minutes  
(cumulative over a 24-hour period). However, it depends on the exposure level  
and setting; for example, in the setting of an aerosol-generating procedure in  
healthcare settings without proper personal protective equipment (PPE), this may  
be defined as any duration.  
Criteria to Distinguish a New Case from an Existing Case  
The following should be enumerated as a new case:  
SARS-CoV-2 sequencing results from the new positive specimen and a positive specimen from the most recent previous case demonstrate a different lineage,  
OR  
Person was most recently enumerated as a confirmed or probable case with onset date (if available) or first positive specimen collection date for that classification >90 days prior  
‡  
,  
OR  
Person was previously reported but not enumerated as a confirmed or probable case (i.e., suspect)  
‡‡  
, but now meets the criteria for a confirmed or probable case.  
‡  
Some individuals, e.g., severely immunocompromised persons, can shed  
SARS-CoV-2 detected by molecular amplification tests >90 days after  
infection. For severely immunocompromised individuals, clinical judgment  
should be used to determine if a repeat positive test is likely to result from  
long-term shedding and, therefore, not be enumerated as a new case. CDC  
defines severe immunocompromise as certain conditions, such as being on  
chemotherapy for cancer, untreated human immunodeficiency virus (HIV)  
infection with CD4 T lymphocyte  
count <200, combined primary immunodeficiency disorder, and receipt of  
prednisone >20mg/day for more than 14 days.  
‡‡  
Repeat suspect cases should not be enumerated.  
Case Classification  
Suspect  
Meets supportive laboratory evidence  
††  
with no prior history of being a confirmed or probable case.  
††  
For suspect cases, jurisdictions may opt to place them in a registry for other epidemiological analyses or investigate to determine probable or confirmed status.  
Probable  
Meets clinical criteria  
AND  
epidemiologic linkage with no confirmatory or presumptive laboratory evidence for SARS-CoV-2,  
OR  
Meets presumptive laboratory evidence,  
OR  
Meets vital records criteria with no confirmatory laboratory evidence for SARS-CoV-2.  
Confirmed  
Meets confirmatory laboratory evidence.  
Other Criteria  
Vital Records Criteria  
A death certificate that lists COVID-19 disease or SARS-CoV-2 or an equivalent term as an underlying cause of death or a significant condition contributing to death.  
References  
The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145–151. DOI:10.3760/cma.j.issn.0254-6450.2020.02.003.  
Wang J, Kaperak C, Sato T, Sakuraba A. COVID-19 reinfection: A Rapid Systematic Review of Case Reports and Case Series. medRxiv. 2021 https://jim.bmj.com/content/69/6/1253.  
FDA Emergency Use Authorizations https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations and https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-testing-sars-cov-2#nolonger.  
Related Case Definition(s)  
Coronavirus Disease 2019 (COVID-19) | 2025 Case Definition  
Coronavirus Disease 2019 (COVID-19) | 2023 Case Definition  
Coronavirus Disease 2019 (COVID-19) | 2020 Interim Case Definition, Approved August 5, 2020  
Coronavirus Disease 2019 (COVID-19) | 2020 Interim Case Definition, Approved April 5, 2020  
Back to Top  
Sources  
Print  
Share  
Facebook  
LinkedIn  
Twitter  
Syndicate  
Content Source:  
Case Definitions  
Message Mapping Guides  
Supporting Documents for Implementation  
Event Codes & Other Surveillance Resources  
National Notifiable Diseases Surveillance System (NNDSS)  
NNDSS receives and shares case data from state, local, and territorial health departments to help public health monitor, control, and prevent serious diseases.  
View All  
About About National Notifiable Diseases Surveillance System  
What is Case Surveillance?  
Case Surveillance Modernization  
Infectious Disease Tables  
Non-Infectious Disease Data  
Technical Resource Center  
Case Surveillance in Action  
Contact Us  
View All  
Sign up for Email Updates  
Contact CDC  
Organization  
Policies  
Web Policies  
Languages  
Languages  
Español  
Language Assistance  
Archive  
CDC Archive  
Public Health Publications  
Contact Us  
About CDC  
Organization  
Policies  
Web Policies  
Languages  
Languages  
Español  
Language Assistance  
Archive  
CDC Archive  
Public Health Publications  
HHS.gov  
USA.gov